Carregant...
Treatment of a mouse model of ankylosing spondylitis with exogenous sclerostin has no effect on disease progression
BACKGROUND: No treatment to date is available which specifically targets bone formation in ankylosing spondylitis (AS). Several recent studies have shown that sclerostin (SOST), a Wnt inhibitor specific to osteocytes and chondrocytes, is down-regulated in AS patients. This suggests Wnt signalling ma...
Guardat en:
| Publicat a: | BMC Musculoskelet Disord |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4662039/ https://ncbi.nlm.nih.gov/pubmed/26612313 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12891-015-0823-8 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|